Compare ALC & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALC | IQV |
|---|---|---|
| Founded | 1945 | 1982 |
| Country | Switzerland | United States |
| Employees | N/A | 93000 |
| Industry | Ophthalmic Goods | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.0B | 41.3B |
| IPO Year | 2002 | 2013 |
| Metric | ALC | IQV |
|---|---|---|
| Price | $81.37 | $175.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 16 |
| Target Price | $89.21 | ★ $232.56 |
| AVG Volume (30 Days) | 1.8M | ★ 2.9M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 7.84 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $8.01 | $6.76 |
| Revenue Next Year | $6.43 | $5.85 |
| P/E Ratio | $38.31 | ★ $22.73 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $71.55 | $134.65 |
| 52 Week High | $99.20 | $247.05 |
| Indicator | ALC | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 47.00 | 41.22 |
| Support Level | $77.10 | $156.43 |
| Resistance Level | $81.84 | $193.26 |
| Average True Range (ATR) | 1.64 | 6.74 |
| MACD | -0.20 | 3.07 |
| Stochastic Oscillator | 24.37 | 66.38 |
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.